big tech funding

2 Houston startup founders score cash prizes from Google's diversity-focused funds

Google for Startups Latino Founders Fund and Black Founders Fund announced their latest cohorts and two Houston founders made the cut. Photo via Getty Images

Two Houston startups have received funding from Google in the latest round of the tech giant's Founders Funds grants.

That's Clutch, a creator economy platform that connects emerging brands with its network of digital marketing professionals, was named to the second cohort of Google for Startups Latino Founders Fund. And SmartWiz, an AI enabled IRS approved tax professional software, was named to Google for Startups' sixth Black Founders Fund.

Both startups will receive $150,000 in non-dilutive funds, mentorship, access to programs, and other resources like sales training, investor prep, mental health coaching at no cost.

Madison Long, CEO and Co-founder at That’s Clutch said the funds will help That's Clutch build upon it's go to market strategy and sales strategy, among other benefits.

“The Google for Startups support network has introduced me to so many valuable connections across the country,” Long said in a statement. “Being selected for the Founders Fund is not only an honor but a massive resource as we take Clutch to the next level."

Madison Long of That's Clutch joins the 448 founders who have been supported by Google's funds. Photo courtesy

Bre Johnson — who is based in Houston, while her company SmartWiz is headquartered in Birmingham, Alabama — told Innovation Map that the funds and partnership with Google will help her company scale and improve their AI platform for the tax industry.

"This funding (gives) us the ability to build our product faster, scale our organization and really take over the digital space with improved support on how we market our software using Google SEO," she says. "We will be giving our users a more innovative, fun and revolutionary approach to tax preparation while ensuring every single person who gets their taxes done by someone using our software will have an improved experience every single year."

"Being black founders, and even me being a woman, we don't take this opportunity for granted because we know that it is a blessing," she continues.

Bre Johnson of SmartWiz also received funding from Google. Photo courtesy

That's Clutch and SmartWiz are among the 448 founders Google has backed through its Founder Funds globally since 2020. Five other Texas-based startups received funding this round, according to an announcement.

Other Texas startups include:

Last year, three Houston startups were named to the inaugural Google for Startups Latino Founders Fund: AnswerBite, Boxes and Ease. That same year, ChurchSpace and Enrichly were named to the Google for Startups Black Founders Fund.

Ease, a health care fintech platform founded by Mario Amaro in 2018, was also named to Amazon's WS Impact Accelerator Latino Founders Cohort, part of Amazon's $30 million commitment to supporting underrepresented startup founders, earlier this summer.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted